NOTAS Y REFERENCIAS BIBLIOGRÁFICAS
1.- Dove A. Maurice Hilleman. Nat Med. 2005 Apr; 11(4 Suppl): S2.
El artículo recoge testimonios sobre la figura de Hilleman con ocasión de un homenaje que le dieron sus colegas el 26 de enero en Filadelfia. Curiosamente, aparece en la revista el mismo mes de su óbito y la reseña del volumen y el suplemento coinciden con la fecha exacta del mismo, otra casualidad que hubiera hecho las delicias del humor negro de Hilleman.
2.- Hilleman MR. Six decades of vaccine development-a personal history. Nat Med. 1998 May;4(5 Suppl):507-14
3.- Hilleman MR. Personal historical chronicle of six decades of basic and applied research in virology, immunology, and vaccinology. Immunol Rev. 1999 Aug;170:7-27.
4.- Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine. 2000 Feb 14; 18(15):1436-47.
5.- Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. J Hum Virol. 2000 Mar-Apr; 3(2):63-76.
6.- Plotkin SA. The late sequelae of Arrowsmith. Pediatr Infect Dis J. 2002 Sep; 21(9):807-9. Es un resumen de su discurso de aceptación de la Albert Sabin Gold Medal de 2002, otorgada por la Sabin Foundation, honor que también recibió Hilleman en 1997.
7.- Sinclair Lewis, Premio Nobel de Literatura en 1930, obtuvo por esta novela el Pulitzer de 1925. El protagonista Martin Arrowsmith es un joven que tras estudiar medicina encontrará en Max Gottlieb, un huraño investigador, al mentor que le encaminará al estudio de la inmunología como campo de investigación. La novela se adentra en las dudas de Martin sobre el ejercicio de la medicina como clínico, que le reportará fama y dinero o la soledad del laboratorio. También muestra la feroz competitividad entre laboratorios de la industria por conseguir resultados y patentes. Lewis fue asesorado para escribirla por su amigo Paul De Kruif, un bacteriólogo autor de “Cazadores de microbios” (1926), excelente perspectiva novelada de las vidas de Pasteur, Roux, Bruce, Reed, Koch, Ehrlich y un largo etcétera de investigadores. Ambas lecturas de innegable interés para los vacunólogos.
8.- Los libros editados por Hilleman son: “The induction of interferon”, ed. W.H. Freeman (1971), “Immunological studies on the psittacosis-lymphogranuloma group of viral agents” , “DNA Vaccines: A New Era in Vaccinology” con Liu M y Kurth R como coeditores, ed. New York Academy of Sciences (1995) y “Assessment and Management of Risks Associated With Hepatitis B: Effectiveness of Intervention”, con Douglas RG como coeditor, ed. Hanley & Belfus (1991). Ha participado escribiendo capítulos en otros como “Vaccinia, vaccination, vaccinology” de Plotkin y Fantini, ed. Elsevier, 1996, donde se encarga de dos revisiones, la dedicada a las vacunas frente a hepatitis y la de parotiditis.
9.- Sela M, Hilleman MR. Therapeutic vaccines: realities of today and hopes for tomorrow. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14559. Epub 2004 Sep 21. Su último artículo referenciado en Medline.
10.- Hilleman MR. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine. 2003 Dec 1;21(32):4626-49
11.- Hilleman MR. Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14560-6. Epub 2004 Aug 5
12.- Hilleman MR. Personal reflections on twentieth century vaccinology. Southeast Asian J Trop Med Public Health. 2003 Jun;34(2):244-8
13.- Hilleman MR. Overview of the needs and realities for developing new and improved vaccines in the 21st century. Intervirology. 2002; 45(4-6):199-211.
14.- Hilleman MR. Overview: past and future of immunologic intervention in the pathogenesis, prophylaxis and therapeusis of hepatitis B. J Gastroenterol Hepatol. 2002 Dec;17 Suppl:S449-51
15.- Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine. 2002 Aug 19;20(25-26):3068-87
16.- Hilleman MR. DNA vectors. Precedents and safety. Ann N Y Acad Sci. 1995 Nov 27;772:1-14
17.- Hilleman MR. Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine. 2001 Dec 12;20(5-6):651-65
18.- Hilleman MR. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine. 2001 Feb 28;19(15-16):1837-48
19.- Hilleman MR. Overview of vaccinology with special reference to papillomavirus vaccines. J Clin Virol. 2000 Oct;19(1-2):79-90
20.- Hilleman MR. Overview of viruses, cancer, and vaccines in concept and in reality. Recent Results Cancer Res. 1998;154:345-62
21.- Hilleman MR. Discovery of simian virus 40 (SV40) and its relationship to poliomyelitis virus vaccines. Dev Biol Stand. 1998;94:183-90
22.- Hilleman MR. A simplified vaccinologists’ vaccinology and the pursuit of a vaccine against AIDS. Vaccine. 1998 May;16(8):778-93
23.- Hilleman MR. Strategies for the achievement of prophylactic vaccination against HIV. Antibiot Chemother. 1996;48:161-72
24.- Hilleman MR. Overview: practical insights from comparative immunology and pathogenesis of AIDS, hepatitis B, and measles for developing an HIV vaccine. Vaccine. 1995 Dec;13(18):1733-40
25.- Hilleman MR. Whether and when an AIDS vaccine? Nat Med. 1995 Nov;1(11):1126-9
26.- Hilleman MR. Viral vaccines in historical perspective. Dev Biol Stand. 1995;84:107-16
27.- Hilleman MR. Comparative biology and pathogenesis of AIDS and hepatitis B viruses: related but different. AIDS Res Hum Retroviruses. 1994 Nov;10(11):1409-19
28.- Hilleman MR. Vaccinology, immunology, and comparative pathogenesis of measles in the quest for a preventative against AIDS. AIDS Res Hum Retroviruses. 1994 Jan;10(1):3-12
29.- Hilleman MR. Recombinant vector vaccines in vaccinology. Dev Biol Stand. 1994;82:3-20
30.- Hilleman MR. The promise and the reality of viral vaccines against cancer. Ann N Y Acad Sci. 1993 Aug 12;690:6-18
31.- Hilleman MR. Hepatitis and hepatitis A vaccine: a glimpse of history. J Hepatol. 1993;18 Suppl 2:S5-10
32.- Hilleman MR. The dilemma of AIDS vaccine and therapy. Possible clues from comparative pathogenesis with measles. AIDS Res Hum Retroviruses. 1992 Oct;8(10):1743-7.
33.- Hilleman MR. Past, present, and future of measles, mumps, and rubella virus vaccines. Pediatrics. 1992 Jul;90(1 Pt 2):149-53.
34.- Hilleman MR. Historical and contemporary perspectives in vaccine developments: from the vantage of cancer. Prog Med Virol. 1992;39:1-18.
35.- Hilleman MR. Impediments, imponderables and alternatives in the attempt to develop an effective vaccine against AIDS. Vaccine. 1992;10(14):1053-8.
36.- Hilleman MR. History, precedent, and progress in the development of mammalian cell culture systems for preparing vaccines: safety considerations revisited. J Med Virol. 1990 May;31(1):5-12
37.- Hilleman MR. Conclusions: in pursuit of an AIDS virus vaccine. Immunol Ser. 1989;44:605-20.
38- Hilleman MR. Present status of recombinant hepatitis B vaccine. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1988 Dec;29 Suppl B:8B-15B.
39.- Hilleman MR. Hepatitis B and AIDS and the promise for their control by vaccines. Vaccine. 1988 Apr;6(2):175-9.
40.-Hilleman MR. Yeast recombinant hepatitis B vaccine. Infection. 1987 Jan-Feb;15(1):3-7.
41.- Hilleman MR. The science of vaccines in present and future perspective. Med J Aust. 1986 Mar 31;144(7): 360-4.
42.- Hilleman MR. Recombinant yeast hepatitis B vaccine. Dev Biol Stand. 1986;63:57-62.
43.- Collins H. The man who saved your life- Maurice Hilleman- Developer of vaccines for Mumps and Pandemic Flu. Philadelphia Enquirer, August 30, 1999. Artículo de prensa publicado el día que cumplió ochenta años.
44.- Allen A. The Unsung Vaccinologist. Maurice Hilleman deserves the praise being lavished on Jonas Salk. Slate Magazine, Abril 13, 2005.
45.- Hilleman MR, Gordon FB. Immunologic relations of the psittacosis-lymphogranuloma group of viral agents. Proc. Soc. Exper. Biol. & Med. 1944, 56, 159-161
46.- Hilleman MR. Immunological studies on the psittacosis-lymphogranuloma group of viral agents. J. Infect. Dis. 1945, 76, 96-114
47.- Hilleman MR, Mason RP, Rogers NG. Laboratory studies on the 1950 outbreak of influenza. Public Health Rep. 1950 Jun 16;65(24):771-7
48.- Hilleman MR, Mason RP, Buescher EL. Antigenic pattern of strains of influenza A and B. Proc Soc Exp Biol Med. 1950 Dec;75(3):829-35
49.- Hilleman MR. System for measuring and designating antigenic components of influenza viruses with analyses of recently isolated strains. Proc Soc Exp Biol Med. 1951 Oct;78(1):208-15
50.- Hilleman MR. Vaccines, human experimentation, and ethics in evolutionary perspective. Dev Biol Stand. 1998;95:13-7
51.- Hilleman MR. Cooperation between government and industry in combating a perceived emerging pandemic. The 1976 swine influenza vaccination program. JAMA. 1996 Jan 17;275(3):241-3
52.- Hilleman MR. Overview: cause and prevention in biowarfare and bioterrorism. Vaccine. 2002 Aug 19;20(25-26):3055-67
53.- Hilleman MR. International biological standardization in historic and contemporary perspective. Dev Biol Stand. 1999;100:19-30
54.- Hilleman MR. The business of science and the science of business in the quest for an AIDS vaccine. Vaccine. 1999 Mar 5;17(9-10):1211-22
55.- McAleer WJ, Markus HZ, McLean AA, Buynak EB, Hilleman MR. Stability on storage at various temperatures of live measles, mumps and rubella virus vaccines in new stabilizer.J Biol Stand. 1980;8(4):281-7
56.- Hilleman MR. Improving the heat stability of vaccines: problems, needs, and approaches. Rev Infect Dis. 1989 May-Jun;11 Suppl 3: S613-6
57.- Hilleman MR. Vaccinology in practical perspective. Dev Biol Stand. 1986; 63:5-13
58.- Proceedings of the Dr. Maurice Hilleman Symposium, August 30, 1999 , in honor of his 80th birthday. J Hum Virol. 2000 Mar-Apr; 3(2):59-112
